St. Louis-based Ascension Ventures and Labcorp have invested in a strategic financing round for Cofactor Genomics.
The company’s flagship test, OncoPrism, uses machine learning to analyze tumors and predict how they will respond to immunotherapy drugs.
“We partner with companies that can meaningfully impact care delivery across our health system partners,” said John Kuelper, senior managing director of Ascension Ventures, in a Dec. 15 news release. “Cofactor’s technology has the potential to change how immunotherapy decisions are made for a significant portion of U.S. cancer patients.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.